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Suicide is a tragic culmination of the interaction of a
wide array of factors, including biological, sociocultural,
environmental, and psychological causes. Suicide claims
approximately 1 million lives worldwide every year; despite
this suicide receives relatively less attention than it deserves,
resulting in a lack of emphasis in research and fragmented
preventive approaches. Understanding and utilizing the correct
terminology in regard to suicide is important. This includes
definitions for suicide, suicidal behavior, suicide attempts,
suicidal ideation (SI), suicide loss survivors, attempt survivors,
nonsuicidal self‑injurious (NSSI) behavior, and commonly
unacceptable terminology. The term survivor in the suicide
prevention field is not used in the same way as other fields,
for example, cancer survivors. Rather, the term refers to
individuals who have lost loved ones, colleagues, and friends
to suicide. Instead, individuals who have survived their own
suicide attempts refer to themselves as individuals with lived
experience. Individuals demonstrating NSSI behavior, while
they may not be suicidal in the moment, they are exhibiting
such behavior although half of this population will attempt to
take their own lives at some later point in time.
Unacceptable terminology is an issue; for example, the term
suicidality is particularly problematic, as it often applies to a
broad range of concepts and is too vague for a definition of an
individual’s behavior. For the public at large, the cultural shifts
in advocacy have created a movement away from pejorative
terminology, such as “failed” or “successful” attempts, as
they indicate valence toward the individual’s actions that
are in direct opposition to our intended conversation. As an
additional point, the phrase “committed suicide” is not one
that the suicide prevention community utilizes anymore, as
it is indicative of historically religious or moral implications
instead of health‑driven outcomes.
From the perspective of the clinician, it is important to
understand that risk factors do not always reveal themselves
immediately. Suicide risk changes overtime. It is important

to continually “tune in” to individuals, especially during
times of change, which can help to identify individuals at risk
throughout their care, not just when they are exhibiting clear
SI. A good understanding of and highlighting protective factors
specific to the patient is important. While dealing with patients
through the lens of what makes them special or unique can
provide a reminder to patients about their importance, their
value, and the positive in their lives.
Research shows that suicide is multifactorial. Factors
discussed that elevate suicide lifetime risk includes personality
disorders/traits, substance use/abuse, impulsivity, access to
lethal means, suicidal behavior, life stressors, psychological
vulnerability, family history, hopelessness, neurobiology, and
serious or other psychiatric illnesses. It is important to note
that there is a difference between risk factors, which endure
over time, and warning signs that may signal imminent suicide
risk. A further discussion of specific warning signs, coalescing
around talk, behavior, and mood changes follows.
Routine screening for suicide risk and helping those at risk
receive appropriate care may help to prevent many suicide
deaths. However, we assume that screening accurately
identifies those at imminent risk and that patients who are
suicidal are willing to seek treatment. Further, the assumption
is made that established interventions are effective. None of
these assumptions are certain, but all three have the potential
to lower suicide rates with success likely to be greatest when
all three are implemented consecutively.
Certain medications have been found to have antisuicidal
effects independent of their action on the primary psychiatric
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disorder. Examples are lithium in mood disorders, clozapine
in psychosis, and ketamine for mood disorders. However,
engaging individuals who are suicidal to seek and remain in
treatment is challenging. Many refuse the care altogether;
others drop out after only a few sessions. Moreover, most of
those who die by suicide did not receive any mental health
care in the months before their death.
Cognitive behavior therapy and dialectical behavior therapy
are some of the evidence‑based suicide‑specific psychosocial
treatments reducing suicidality in certain populations. They
are effective in reducing the onset of SI, posttreatment suicide
attempts and reattempts, hospitalizations, and emergency
department (ED) visits apart from the medical risk of
self‑injurious acts.
Stabilization‑oriented interventions such as safety planning and
crisis response planning are increasingly popular, as they have
been shown to result in significantly fewer suicide attempts,
lower SI, and greater treatment engagement. These include, to
identify personalized warning signs and to determine internal
coping strategies that distract from suicidal thoughts and urges.
To identify family and friends who are able to distract from
suicidal thoughts and urges. Further to identify individuals who
can help to provide support during a suicidal crisis including
a list of mental health professionals and urgent care services
that can be contacted during a suicidal crisis.
Whereas we have the information needed to identify those
patients most at risk for suicide and effective screening tools;
these assessments do not take place routinely. This is proven
by the statistics that within 1 month of a suicide attempt
every three out of five individuals had a health‑care visit of
any type, and two out of five of these had a mental health
visit. Several key barriers contribute to this gap. First, until
recently, suicide care has not been seen as a core responsibility
of health‑care settings. This unfortunate and unacceptable
trend is rationalized in many ways, such as “of course suicide
is a tragedy, but there is really nothing we can do.” Second,
myths about suicide have been accepted as true in health‑care
settings. For instance, one widespread myth is that asking
people about suicide encourages them to complete it. This myth
contributes to a failure to ask about suicide risk. Third, most
health‑care professionals are not aware of newly developed
brief interventions for suicide, leading to the assumption that
they should not ask about suicide, because there is nothing
practical that can be done in ordinary health‑care settings.
The reasons for this gap between science and practice are
many. There is an absence of standardized assessment protocols
across health settings. Nonmental health clinical professionals
are concerned about their ability to find treatment services
for individuals who are at risk. There is also a general lack
of awareness and acknowledgment of “critical assessment
windows,” which are the time periods when these people
are the most at risk of suicide ideation. These time windows
include the week after a visit to the ED for substance abuse,
the week after discharge from psychiatric hospitalization,
152

and the 1st weeks after starting an antidepressant. These are
crucial time periods but there is no standardization of screening
practice, which results in missing the opportunity to intervene.
Frequently, when someone dies by suicide, we hear “he fell
through the cracks.” Health‑care settings are well positioned
to help prevent this from happening. However, care for people
with suicide risk is highly variable, common gaps in care for
individuals at risk of suicide do exist, and recommendations
are needed to close these gaps.
Current practice for people who acknowledge suicidal thoughts
or feelings often revolves around a decision of whether to
hospitalize them or send them home, perhaps with a future
appointment for mental health treatment. Unfortunately,
neither of these options often adequately address the risks
of suicide or the needs of suicidal people. Inpatient care
may keep people safe for the few days they are hospitalized.
However, very brief stays are not long enough to get many
suicidal people through their period of elevated risk, and they
are often discharged while still in a state of elevated risk. In
addition, hospitalization usually does not directly address
suicidal thought patterns, relying on the hope that treatment
for other psychiatric problems is sufficient. However, this may
not be true. As a result, suicide rates for the days and weeks
immediately after hospitalization are extremely high.
In view of the diversity and heterogeneity of epidemiologic
patterns and risk or protective factors for suicide, prevention
programs should be closely examined to determine whether
they are directly relevant to local situations. Given the limited
resources provided, understanding and implementing suicide
prevention programs are extremely challenging and rewarding
in terms of making a considerable impact on preventing a large
number of suicides.

What Can We Do?
Timely supportive contacts (such as calls, texts, letters, and
visits) should be standard for people with significant suicide
risk after acute care episodes or when ongoing services are
interrupted (e.g., a scheduled visit is missed). These caring
contacts with high‑risk individuals have been demonstrated
to be effective in reducing suicide.

Promising Biomarkers to Predict Suicide Risk
Predicting suicidality (SI, suicide attempts, and suicide
completion) in individuals is a difficult task. Widespread use of
risk prediction tests as a part of routine or targeted health‑care
assessments will lead to early disease interception followed
by preventive lifestyle modifications or treatment. Given the
magnitude and urgency of the problem, the importance of
efforts to implement such tools cannot be overstated. Research
newly reported in the Journal of Molecular Psychiatry[1] could
help doctors to identify women who are most at risk for suicide,
using biological markers that can be measured in the blood
and a newly developed clinical assessment. van Heeringen
and Mann[2] discuss the stress–diathesis theory of suicide, in
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which a predisposition or diathesis interacts with stressful
life experiences and acute psychiatric illness to cause suicidal
behavior. The theory explains why only a small minority of
individuals are at risk of taking their own lives after exposure
to such stressors. Postmortem and neuroimaging studies have
identified structural and functional changes in the brains of
individuals with a history of suicidal behavior that may affect
the regulation of mood, response to stress and decision‑making,
and these include biochemical deficits in serotonin function
and the hypothalamic‑pituitary‑adrenal axis stress response.
These abnormalities could be used in the future to develop
biomarkers that may help predict who is at risk of taking their
own lives and that may serve as a target for treatment.

Breakthroughs
Noting the rapid antidepressive effects of ketamine, the
research has demonstrated its effectiveness in emergency
room settings reducing SIs. A sustained decrease in SIs
at 10 days postinfusion has also been reported.[3] Specific
genetics risk factors for suicide can not be distinguished from
coexisting psychiatric conditions; this has led researchers to
study interactions among multiple genes. Comprehensively
understanding epigenetic modifications of gene activity, in
addition to identifying those genes linked to suicide risk could
lead to more effective diagnostic tools that could, in turn,
enable more effective interventions for those at highest risk.

Challenges Ahead
Despite the progress in suicide prevention globally, we still face
numerous challenges. The accuracy and reliability of suicide
statistics are an ongoing issue of concern in a considerable
number of countries. Ongoing challenges include insufficient
resources, ineffective coordination, lack of enforcement of
guidelines, limited access to surveillance data on suicide
and attempted suicide or self‑harm, and lack of independent
and systematic evaluations.[4] Many challenges remain; first,
our ability to predict suicide is still not much better than
chance, and although there has been a welcome focus on
suicide prevention interventions (both at the public health and
clinical level), many gaps in our knowledge remain. Finally,
we are optimistic that the new developments and the field’s
determination to overcome the identified challenges will
combine to save more lives across the globe.
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